Darunavir: 6 agencies, 2007–2023
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AWMSG (Wales) has been easier on darunavir than on its own caseload: it refused 1 of 6 decisive submissions here (17%), against a base rate of 49% across everything it has assessed.
The file has been open for more than a decade: 16.3 years separate the first record, 30 Mar 2007 at TLV (Sweden), from the most recent, 5 Jul 2023 at CONITEC (Brazil).
SMC (Scotland) changed its position: recommended on 8 Feb 2010, restricted by 13 Jul 2015.
No assessment is on file from HAS (France), PBAC (Australia) and G-BA (Germany), each among the eight highest-volume agencies here.
The programme is broad: 10 distinct indication wordings are recorded for darunavir by the agencies that label one in English (AWMSG and SMC).
TLV (Sweden) was first to assess darunavir, on 30 Mar 2007; CIPM (Spain) did not open a file until 10 Jun 2021 — an unusually long tail of 14.2 years between the earliest and latest system to look at it.
The record arrives in waves: 5 separate years each carry two or more decisions, spread across 11 years in total.
5 of the 6 agencies here assessed darunavir more than once, AWMSG (Wales) most often at 7 entries — repeat review is the norm for this molecule rather than the exception.
6 of the 18 agencies in this archive hold a record for darunavir.
The full ledger for darunavir reads 14 recommended, 3 restricted, 1 not recommended and 1 not assessed, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CONITEC (Brazil) | 5 Jul 2023 | Tratamento do vírus da imunodeficiência humana (HIV). | incorporated into SUS | source |
| CIPM (Spain) | 10 Jun 2021 | Indicaciones terapéuticas autorizadas: Rezolsta está indicado en combinación con otros medicamentos antirretrovirales, p… | financed by the SNS · art. 92 a, b | source |
| SMC (Scotland) | 13 Jul 2015 | Once daily darunavir co-administered with low dose ritonavir in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus… | accepted (restricted) | source |
| AWMSG (Wales) | 10 Mar 2015 | Co-administered with cobicistat in combination with other antiretroviral (ART) medicinal products for the treatment of h… | not endorsed (non-submission) | source |
| TLV (Sweden) | 25 Nov 2013 | Nya styrkor av Prezista tabletter ingår i högkostnadsskyddet | general subsidy | source |
15 further decisions for darunavir, across 5 agencies, are not shown here. They link to 14 further source documents.
Related molecules
- raltegravir — divergent outcome (recommended vs restricted) on a shared indication
- sofosbuvir — same ATC class J05A — Antivirals
- letermovir — same ATC class J05A — Antivirals
- cabotegravir — same ATC class J05A — Antivirals
- tenofovir — same ATC class J05A — Antivirals
- dolutegravir — same ATC class J05A — Antivirals
Coverage: 20 decisions for darunavir from 6 agencies, 2007 to 2023. Data to 7 Sep 2026. ATC class J05A — Antivirals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.